These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29293244)

  • 1. Cancer immunotherapy.
    Bender E
    Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
    [No Abstract]   [Full Text] [Related]  

  • 2. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
    Nelson B
    Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety concerns blight promising cancer therapy.
    Ledford H
    Nature; 2016 Oct; 538(7624):150-151. PubMed ID: 27734893
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer Immunotherapy: Theory and Application.
    Chen G; Bodogai M; Tamehiro N; Shen C; Dou J
    J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 6. Attack of the killer clones.
    Scudellari M
    Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233
    [No Abstract]   [Full Text] [Related]  

  • 7. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
    Jäger E; Jäger D; Knuth A
    Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
    [No Abstract]   [Full Text] [Related]  

  • 8. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manufacturing genetically modified T cells for clinical trials.
    Gee AP
    Cancer Gene Ther; 2015 Mar; 22(2):67-71. PubMed ID: 25633481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: translation from mice to human clinical trials.
    Maeng H; Terabe M; Berzofsky JA
    Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When transgenes shape immunity: cancer immune-gene therapy.
    Bonini C; Parmiani G
    J Gene Med; 2012 Jun; 14(6):384-5. PubMed ID: 22736622
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Tumor Antigens and Cancer Immunotherapy.
    Vigneron N
    Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
    Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of immunotherapy drug combinations and biomarkers.
    Schmidt C
    J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
    [No Abstract]   [Full Text] [Related]  

  • 20. Glioma antigen.
    Toda M
    Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.